UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets

Nature communications, 2021-07, Vol.12 (1), p.4612-4612, Article 4612

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial

British journal of cancer, 2020-03, Vol.122 (5), p.634-639

2020

Link zum Volltext

Verfügbarkeit prüfen

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study

Journal of surgical oncology, 2018-11, Vol.118 (6), p.1021-1026

2018

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634

Cancers, 2021-07, Vol.13 (15), p.3741

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

Clinical cancer research, 2013-11, Vol.19 (22), p.6296-6304

2013

Link zum Volltext

Verfügbarkeit prüfen

Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study

Cancers, 2021-08, Vol.13 (16), p.3991

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

Investigational new drugs, 2013-04, Vol.31 (2), p.399-408

2013

Link zum Volltext

Verfügbarkeit prüfen

Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy

Cancers, 2021-10, Vol.13 (21), p.5427

2021

Link zum Volltext

Verfügbarkeit prüfen

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

European journal of cancer (1990), 2006-12, Vol.42 (18), p.3127-3139

2006

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

British journal of cancer, 2021-01, Vol.124 (2), p.391-398

2021

Link zum Volltext

Verfügbarkeit prüfen

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform

The lancet oncology, 2022-02, Vol.23 (2), p.198-201

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

Cancer chemotherapy and pharmacology, 2008-03, Vol.61 (3), p.435-441

2008

Link zum Volltext

Verfügbarkeit prüfen

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension

British journal of cancer, 2023-01, Vol.128 (2), p.354-362

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

British journal of cancer, 2020-04, Vol.122 (8), p.1166-1174

2020

Link zum Volltext

Verfügbarkeit prüfen

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Clinical cancer research, 2011-11, Vol.17 (22), p.7156-7163

2011

Link zum Volltext

Verfügbarkeit prüfen

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib

Liver international, 2020-01, Vol.40 (1), p.215-228

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5094-5101

2009

Link zum Volltext

Verfügbarkeit prüfen

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?

European journal of cancer (1990), 2008-11, Vol.44 (16), p.2350-2356

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-01, Vol.11 (2), p.703-711

2005

Link zum Volltext

Verfügbarkeit prüfen

The yield of chest computed tomography in patients with locally advanced pancreatic cancer

Journal of surgical oncology, 2020-09, Vol.122 (3), p.450-456

2020

Link zum Volltext

Verfügbarkeit prüfen

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Clinical cancer research, 2009-09, Vol.15 (17), p.5584-5590

2009

Link zum Volltext

Verfügbarkeit prüfen

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

European journal of cancer (1990), 2021-03, Vol.145, p.132-142

2021

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2022-10, Vol.10 (10), p.e005471

2022

Link zum Volltext

Verfügbarkeit prüfen

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma

Frontiers in endocrinology (Lausanne), 2021-03, Vol.12, p.627819-627819

2021

Link zum Volltext

Verfügbarkeit prüfen

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial

European journal of cancer (1990), 2010-12, Vol.46 (18), p.3200-3204

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(88)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets

Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

The yield of chest computed tomography in patients with locally advanced pancreatic cancer

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial

Suchergebnisse filtern